fumonisin b1

fumonisin b1 is a lipid of Sphingolipids (SP) class. Fumonisin b1 is associated with abnormalities such as Infection, Kidney Diseases, Liver diseases, DERMATITIS HERPETIFORMIS, FAMILIAL and Malnutrition. The involved functions are known as Gene Expression, Anabolism, Signal, Biosynthetic Pathways and Regulation. Fumonisin b1 often locates in Body tissue, Microsomes, microsomal membrane, Protoplasm and Mitochondria. The associated genes with fumonisin b1 are Genome, P4HTM gene, FATE1 gene, BCL2 gene and TMEM132D gene. The related lipids are dihydroceramide, ceramide 1-phosphate, Sphingolipids, Fatty Acids and Palmitates.

Cross Reference

Introduction

To understand associated biological information of fumonisin b1, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with fumonisin b1?

fumonisin b1 is suspected in Infection, Kidney Diseases, Liver diseases, DERMATITIS HERPETIFORMIS, FAMILIAL, Malnutrition, Celiac Disease and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with fumonisin b1

MeSH term MeSH ID Detail
Stomach Ulcer D013276 75 associated lipids
Adenocarcinoma D000230 166 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Kidney Neoplasms D007680 29 associated lipids
Inflammation D007249 119 associated lipids
Fatty Liver D005234 48 associated lipids
Body Weight D001835 333 associated lipids
Esophageal Neoplasms D004938 20 associated lipids
Precancerous Conditions D011230 48 associated lipids
Carcinoma D002277 18 associated lipids
Pulmonary Edema D011654 23 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Testicular Diseases D013733 15 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Asthma D001249 52 associated lipids
Kidney Diseases D007674 29 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Chemical and Drug Induced Liver Injury D056486 39 associated lipids
Liver Neoplasms, Experimental D008114 46 associated lipids
Hyperplasia D006965 34 associated lipids
Magnesium Deficiency D008275 9 associated lipids
Neuroblastoma D009447 66 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Nervous System Diseases D009422 37 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Seizures D012640 87 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Death, Sudden D003645 12 associated lipids
Gaucher Disease D005776 13 associated lipids
Adenoma D000236 40 associated lipids
Pasteurella Infections D010326 8 associated lipids
Swine Diseases D013553 16 associated lipids
Poultry Diseases D011201 21 associated lipids
Hydrocephalus D006849 6 associated lipids
Glioblastoma D005909 27 associated lipids
Neuronal Ceroid-Lipofuscinoses D009472 5 associated lipids
Salmonella Infections, Animal D012481 9 associated lipids
Paralysis D010243 4 associated lipids
Neural Tube Defects D009436 5 associated lipids
Fetal Resorption D005327 15 associated lipids
Cleft Palate D002972 9 associated lipids
Choline Deficiency D002796 16 associated lipids
Stomatitis D013280 14 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Mycoses D009181 18 associated lipids
Per page 10 20 50 100 | Total 54

PubChem Associated disorders and diseases

What pathways are associated with fumonisin b1

Lipid pathways are not clear in current pathway databases. We organized associated pathways with fumonisin b1 through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with fumonisin b1?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with fumonisin b1?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with fumonisin b1?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with fumonisin b1?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with fumonisin b1?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with fumonisin b1

Download all related citations
Per page 10 20 50 100 | Total 1278
Authors Title Published Journal PubMed Link
Gelderblom WC et al. Interaction of fumonisin B(1) and aflatoxin B(1) in a short-term carcinogenesis model in rat liver. 2002 Toxicology pmid:11836022
Sharma N et al. Augmented fumonisin B1 toxicity in co-cultures: evidence for crosstalk between macrophages and non-parenchymatous liver epithelial cells involving proinflammatory cytokines. 2004 Toxicology pmid:15363598
Stockmann-Juvala H et al. Fumonisin B1-induced toxicity and oxidative damage in U-118MG glioblastoma cells. 2004 Toxicology pmid:15337581
Creppy EE et al. Synergistic effects of fumonisin B1 and ochratoxin A: are in vitro cytotoxicity data predictive of in vivo acute toxicity? 2004 Toxicology pmid:15297026
Gelderblom WC et al. Toxicological effects in rats chronically fed low dietary levels of fumonisin B(1). 2001 Toxicology pmid:11295254
Theumer MG et al. Subchronic mycotoxicoses in Wistar rats: assessment of the in vivo and in vitro genotoxicity induced by fumonisins and aflatoxin B(1), and oxidative stress biomarkers status. 2010 Toxicology pmid:20015463
Mobio TA et al. Comparative study of the toxic effects of fumonisin B1 in rat C6 glioma cells and p53-null mouse embryo fibroblasts. 2003 Toxicology pmid:12504343
Biswal SS et al. Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells. 2000 Toxicology pmid:11118669
Sharma RP et al. Decreased fumonisin hepatotoxicity in mice with a targeted deletion of tumor necrosis factor receptor 1. 2001 Toxicology pmid:11250056
Bhandari N et al. Gender-related differences in subacute fumonisin B1 hepatotoxicity in BALB/c mice. 2001 Toxicology pmid:11522378
Mary VS et al. Reactive oxygen species sources and biomolecular oxidative damage induced by aflatoxin B1 and fumonisin B1 in rat spleen mononuclear cells. 2012 Toxicology pmid:22981896
Bouhet S et al. The mycotoxin fumonisin B1 alters the proliferation and the barrier function of porcine intestinal epithelial cells. 2004 Toxicol. Sci. pmid:14600282
Taranu I et al. Mycotoxin fumonisin B1 alters the cytokine profile and decreases the vaccinal antibody titer in pigs. 2005 Toxicol. Sci. pmid:15659571
Dragan YP et al. Implications of apoptosis for toxicity, carcinogenicity, and risk assessment: fumonisin B(1) as an example. 2001 Toxicol. Sci. pmid:11294969
He Q et al. Silymarin protects against liver damage in BALB/c mice exposed to fumonisin B1 despite increasing accumulation of free sphingoid bases. 2004 Toxicol. Sci. pmid:15103051
He Q et al. Ceramide synthase inhibition by fumonisin B1 treatment activates sphingolipid-metabolizing systems in mouse liver. 2006 Toxicol. Sci. pmid:16960033
Enongene EN et al. Persistence and reversibility of the elevation in free sphingoid bases induced by fumonisin inhibition of ceramide synthase. 2002 Toxicol. Sci. pmid:12011476
Voss KA et al. Reproductive and sphingolipid metabolic effects of fumonisin B(1) and its alkaline hydrolysis product in LM/Bc mice: hydrolyzed fumonisin B(1) did not cause neural tube defects. 2009 Toxicol. Sci. pmid:19783636
Voss KA et al. Toxic effects of fumonisin in mouse liver are independent of the peroxisome proliferator-activated receptor alpha. 2006 Toxicol. Sci. pmid:16221962
Wan LY et al. Modulation of mucin mRNA (MUC5AC and MUC5B) expression and protein production and secretion in Caco-2/HT29-MTX co-cultures following exposure to individual and combined Fusarium mycotoxins. 2014 Toxicol. Sci. pmid:24496642
Mathur S et al. Fumonisin B(1) increases serum sphinganine concentration but does not alter serum sphingosine concentration or induce cardiovascular changes in milk-fed calves. 2001 Toxicol. Sci. pmid:11248151
Mathur S et al. Fumonisin B(1) is hepatotoxic and nephrotoxic in milk-fed calves. 2001 Toxicol. Sci. pmid:11248152
Ferrante MC et al. Effect of fumonisin B1 on structure and function of macrophage plasma membrane. 2002 Toxicol. Lett. pmid:11888701
Bondy GS et al. Retrospective evaluation of serum ornithine carbamyltransferase activity as an index of hepatotoxicity in toxicological studies with rats. 2000 Toxicol. Lett. pmid:10713481
Raynal M et al. Effects of fumonisin B1 present in Fusarium moniliforme culture material on drug metabolising enzyme activities in ducks. 2001 Toxicol. Lett. pmid:11369472
Wan LY et al. Individual and combined effects of Fusarium toxins on the mRNA expression of pro-inflammatory cytokines in swine jejunal epithelial cells. 2013 Toxicol. Lett. pmid:23688591
Steyn PS Mycotoxins, general view, chemistry and structure. 1995 Toxicol. Lett. pmid:8597152
Kuiper-Goodman T Mycotoxins: risk assessment and legislation. 1995 Toxicol. Lett. pmid:8597153
Clarke R et al. High content analysis: a sensitive tool to detect and quantify the cytotoxic, synergistic and antagonistic effects of chemical contaminants in foods. 2015 Toxicol. Lett. pmid:25623391
Chuturgoon AA et al. Fumonisin B₁ modulates expression of human cytochrome P450 1b1 in human hepatoma (Hepg2) cells by repressing Mir-27b. 2014 Toxicol. Lett. pmid:24614526
Fernández-Blanco C et al. An in vitro investigation on the cytotoxic and nuclear receptor transcriptional activity of the mycotoxins fumonisin B1 and beauvericin. 2016 Toxicol. Lett. pmid:27234500
Chuturgoon AA et al. Fumonisin B₁ inhibits apoptosis in HepG2 cells by inducing Birc-8/ILP-2. 2015 Toxicol. Lett. pmid:25800559
He Q et al. Fumonisin-induced tumor necrosis factor-alpha expression in a porcine kidney cell line is independent of sphingoid base accumulation induced by ceramide synthase inhibition. 2001 Toxicol. Appl. Pharmacol. pmid:11437650
Yeung JM et al. Fumonisin B1 induces protein kinase C translocation via direct interaction with diacylglycerol binding site. 1996 Toxicol. Appl. Pharmacol. pmid:8917690
Martinez-Larrañaga MR et al. Induction of cytochrome P4501A1 and P4504A1 activities and peroxisomal proliferation by fumonisin B1. 1996 Toxicol. Appl. Pharmacol. pmid:8917691
Howard PC et al. Comparison of the toxicity of several fumonisin derivatives in a 28-day feeding study with female B6C3F(1) mice. 2002 Toxicol. Appl. Pharmacol. pmid:12498732
Liu BH et al. The effects of mycotoxins, fumonisin B1 and aflatoxin B1, on primary swine alveolar macrophages. 2002 Toxicol. Appl. Pharmacol. pmid:12009859
Ramasamy S et al. Fumonisin B1 alters sphingolipid metabolism and disrupts the barrier function of endothelial cells in culture. 1995 Toxicol. Appl. Pharmacol. pmid:7645031
Riley RT et al. Alteration of tissue and serum sphinganine to sphingosine ratio: an early biomarker of exposure to fumonisin-containing feeds in pigs. 1993 Toxicol. Appl. Pharmacol. pmid:8430417
Cai Q et al. Validation of fumonisin biomarkers in F344 rats. 2007 Toxicol. Appl. Pharmacol. pmid:17904604
Constable PD et al. Ingestion of fumonisin B1-containing culture material decreases cardiac contractility and mechanical efficiency in swine. 2000 Toxicol. Appl. Pharmacol. pmid:10652243
Mobio TA et al. Epigenetic properties of fumonisin B(1): cell cycle arrest and DNA base modification in C6 glioma cells. 2000 Toxicol. Appl. Pharmacol. pmid:10739748
Suzuki CA et al. The effects of fumonisin B1 on several markers of nephrotoxicity in rats. 1995 Toxicol. Appl. Pharmacol. pmid:7645015
Schmelz EM et al. Induction of apoptosis by fumonisin B1 in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. 1998 Toxicol. Appl. Pharmacol. pmid:9473533
Norred WP et al. Mycotoxin-induced elevation of free sphingoid bases in precision-cut rat liver slices: specificity of the response and structure-activity relationships. 1997 Toxicol. Appl. Pharmacol. pmid:9356308
Gardner NM et al. Elevated nuclear sphingoid base-1-phosphates and decreased histone deacetylase activity after fumonisin B1 treatment in mouse embryonic fibroblasts. 2016 Toxicol. Appl. Pharmacol. pmid:26905748
Carlson DB et al. Fumonisin B1 promotes aflatoxin B1 and N-methyl-N'-nitro-nitrosoguanidine-initiated liver tumors in rainbow trout. 2001 Toxicol. Appl. Pharmacol. pmid:11264020
Yoo HS et al. Elevated sphingoid bases and complex sphingolipid depletion as contributing factors in fumonisin-induced cytotoxicity. 1996 Toxicol. Appl. Pharmacol. pmid:8658522
Kim MS et al. Fumonisin B(1) induces apoptosis in LLC-PK(1) renal epithelial cells via a sphinganine- and calmodulin-dependent pathway. 2001 Toxicol. Appl. Pharmacol. pmid:11601888
Gumprecht LA et al. Development of fumonisin-induced hepatotoxicity and pulmonary edema in orally dosed swine: morphological and biochemical alterations. 1998 Nov-Dec Toxicol Pathol pmid:9864095